HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by El-Sayeh, H. G. Articles by Adams, C. E. Search for Related Content PubMed PubMed Citation Articles by El-Sayeh, H. G. Articles by Adams, C. E.

Aripiprazole for schizophrenia

Systematic review

Academic Unit of Psychiatry, University of Leeds, Leeds, UK

C. Morganti, MD

Ospedale Niguarda Ca'Granda, Milan, Italy

C. E. Adams, MRCPsych, MD

Academic Unit of Psychiatry, University of Leeds, Leeds, UK

Correspondence: Dr H.G. El-Sayeh, Briary Wing, Harrogate District Hospital, Lancaster Park Road, Harrogate HG2 7SX, UK. Tel: +44 (0)1423 553 682; fax: +44 (0)1423 553 379; email: hany.el-sayeh{at}chrd-pct.nhs.uk

Declaration of interest None.

Funding detailed in Acknowledgements.

Background Aripiprazole is an atypical antipsychotic that is reported to be effective in the treatment of schizophrenia.

Aims To investigate the effects of aripiprazole on patients with schizophrenia and schizophrenia-like psychoses by conducting a systematic review of randomised controlled trials (RCTs).

Method Database and manual searches and direct contact were used to identify relevant RCTs.

Results We included 10 randomised controlled studies (involving a total of 4125 patients), but study attrition waslarge and the standard of data reporting was poor. Compared with placebo, aripiprazole treatment was associated with a significant decrease in relapse rates, increased compliance with the study protocol, and a decrease in prolactin levels below the expected values. Compared with risperidone, aripiprazole caused less elevation of prolactin levels and less prolongation of the average QTc interval.

Conclusions Aripiprazole has been licensed despite the fact that few reliable data on this drug are publicly available. It may be effective for treatment of schizophrenia, but in terms of tolerability and global outcomes it shows little difference from existing antipsychotics.

Related articles in BJP:

From the Editor's desk

Peter Tyrer
BJP 2006 189: 200. [Full Text]  

This article has been cited by other articles:

				C. Veiga-Martinez, M. Perez-Alvarez, and J. M. Garcia-Montes Acceptance and Commitment Therapy Applied to Treatment of Auditory Hallucinations Clinical Case Studies, April 1, 2008; 7(2): 118 - 135. [Abstract] [PDF]

				R. Hodgson, C. Bushe, and R. Hunter Measurement of long-term outcomes in observational and randomised controlled trials The British Journal of Psychiatry, August 1, 2007; 191(50): s78 - s84. [Abstract] [Full Text] [PDF]

				G. A. Silver, R. Gutierrez-Esteinou, and R. D. McQuade Aripiprazole - data on efficacy and associated mortality The British Journal of Psychiatry, July 1, 2007; 191(1): 86 - 86. [Full Text] [PDF]

				P. Lepping Antipsychotics preferred by mental health professionals Psychiatr. Bull., July 1, 2007; 31(7): 272 - 272. [Full Text] [PDF]

				T. J. Crow Aripiprazole - data on efficacy and associated mortality The British Journal of Psychiatry, July 1, 2007; 191(1): 86 - 87. [Full Text] [PDF]

				P. A. M Mortimer Review: aripiprazole for schizophrenia--more high quality research required Evid. Based Ment. Health, February 1, 2007; 10(1): 14 - 14. [Full Text] [PDF]

eLetters: